MedTrace Logo

Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease

NCT02501876 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2017-04-12

No results posted yet for this study

Summary

In recent years, it has been observed that the type 2 diabetic patients (DM-2) have an increased risk of developing dementia, both vascular and Alzheimer's disease (AD). The term mild cognitive impairment (MCI) describes a transition state between normal cognitive function and dementia. The annual rate of conversion to dementia in MCI patients is around 15% in the general population, regardless of the presence or absence of diabetes. At present it is not possible to identify which patients with MCI are most likely to progress to AD. On this basis, the main objective of this study is to evaluate whether the presence of diabetes and or the presence of its related genes favors the conversion of MCI to AD.

Conditions

  • Alzheimer´s Disease
  • Diabetes Mellitus Type 2

Interventions

OTHER

There is a retrospectiv observational study. No intervention

There is a retrospectiv observational study. No intervention will be performed

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Rafael Simo Canonge, PhD, MD · VHIR Research Institute

Eligibility

Min Age
65 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-09-30
Completion
2016-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02501876 on ClinicalTrials.gov